Could Cytomx Therapeutics Inc (NASDAQ:CTMX) Skyrocket? The Stock Had Too Little Sellers

June 29, 2018 - By Shawn Hawthorne

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Logo

The stock of Cytomx Therapeutics Inc (NASDAQ:CTMX) registered a decrease of 0.9% in short interest. CTMX’s total short interest was 1.03M shares in June as published by FINRA. Its down 0.9% from 1.04M shares, reported previously. With 292,500 shares average volume, it will take short sellers 4 days to cover their CTMX’s short positions. The short interest to Cytomx Therapeutics Inc’s float is 3.76%.

The stock decreased 0.26% or $0.06 during the last trading session, reaching $22.8. About 111,945 shares traded. CytomX Therapeutics, Inc. (NASDAQ:CTMX) has risen 80.84% since June 29, 2017 and is uptrending. It has outperformed by 68.27% the S&P500.

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical firm in the United States. The company has market cap of $888.23 million. The firm develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. It currently has negative earnings. The Company’s other product candidates in preclinical development include CX-2029, CD71, CTLA-4, and CX-188.

More notable recent CytomX Therapeutics, Inc. (NASDAQ:CTMX) news were published by: Benzinga.com which released: “44 Biggest Movers From Yesterday” on June 05, 2018, also Globenewswire.com with their article: “CytomX to Present at the Jefferies 2018 Healthcare Conference” published on May 31, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on June 01, 2018. More interesting news about CytomX Therapeutics, Inc. (NASDAQ:CTMX) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For June 1, 2018” published on June 01, 2018 as well as Nasdaq.com‘s news article titled: “CytomX Announces Appointment of Lloyd A. Rowland Jr. as General Counsel” with publication date: June 14, 2018.

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.